Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD) - Full Text View

Sponsored by:	Imperial College London
Information provided by:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00147082

Purpose

The aim of this study is to investigate the mechanisms whereby leukocytes are recruited to the lung in chronic obstructive pulmonary disease (COPD) and cause tissue destruction. The hypothesis is that in COPD more leukocytes enter the lung and it is these cells that are responsible for the degradation of lung tissue. We, the researchers at Imperial College London, will isolate leukocytes from the blood of patients with COPD, healthy smokers and normal subjects and measure the movement of the leukocytes to chemoattractants. We will examine further, which cell surface receptors are responsible for this trafficking of cells. Furthermore, the differentiation of these cells in vitro will be compared with cells from healthy smokers and normal subjects. Specifically, the expression of enzymes that are responsible for tissue destruction and the cell surface receptors on these cells will be investigated. The objective is to identify the mechanisms whereby leukocytes from COPD patients behave differently to cells from healthy smokers and normal subjects with a view to identify novel targets for drug therapy.

Condition
COPD Emphysema Chronic Bronchitis

MedlinePlus related topics: Bronchitis COPD (Chronic Obstructive Pulmonary Disease) Emphysema

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Retrospective/Prospective Study
Official Title:	Leukocyte Migration and Differentiation in COPD Patients Compared to Healthy Smokers and Healthy Non-Smoking Subjects.

Further study details as provided by Imperial College London:

Estimated Enrollment:	90
Study Start Date:	February 2001
Estimated Study Completion Date:	April 2005

Detailed Description:

Chemotaxis experiments will be performed in order to ascertain the migratory characteristics of leukocytes towards specific chemoattractants. Comparisons of cells from different subjects will be compared. In addition, the effects of various pharmaceutical interventions on this mechanism will also be addressed and compared within subject groups. In some experiments, cells will be differentiated in vitro and their cellular expression and regulation of inflammatory mediators and chemoattractants examined. Again comparisons will be made between subject groups and the efficacy of various pharmacological agents on these cells

Eligibility

Ages Eligible for Study:	21 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy Non-Smoking Subjects. All normal volunteers will meet the following criteria:
- Age 21-70 years.
- No history of respiratory or allergic disease.
- Normal baseline spirometry as predicted for age, sex and height.
- Non-smokers.
- No history of upper respiratory tract infection in the preceding six weeks.
- Not taking regular medication
COPD Subjects. COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines. All COPD volunteers will meet the following criteria:
- Age between 40-75 years.
- A smoking history of at least 20 pack years. (1 pack year = 20 packs of cigarettes per day for 1 year)
- Forced expiratory volume at 1 second : Forced vital capacity (FEV1:FVC) ratio of <0.7, post-bronchodilator FEV1 of <85% predicted, reversibility with inhaled beta2-agonist of <15% of predicted FEV1: all three criteria are required.
- Current smokers or smokers who had ceased smoking for at least 6 months.
- No history of exacerbation, oral steroid or antibiotic use within the preceding 6 weeks.
- Normal serum alpha-1 antitrypsin level.
- No history of other respiratory or allergic disease.
- No evidence of atopy on skin prick testing to common aeroallergens (grass pollen, cat hair, house dust mite or Aspergillus fumigatus
Healthy Smokers. All healthy smoking volunteers in trials will meet the following criteria:
- Age 21-70 years.
- Smoking history of at least 10 pack years. (1 pack year = 10 packs of cigarettes per day for 1 year).
- No history of respiratory or allergic disease.
- Normal baseline spirometry as predicted for age, sex and height.
- No history of upper respiratory tract infection in the preceding six weeks.
- Not taking regular medication.

Exclusion Criteria:

Subjects will not be included in this study if they meet any of the following exclusion criteria:

Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group.
Pregnant women or mothers who are breastfeeding.
Subjects who are unable to give informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00147082

Contacts

Contact: Louise E Donnelly, PhD

0207 352 8121 ext 3061

l.donnelly@imperial.ac.uk

Locations

United Kingdom
Royal Brompton Hospital/NHLI Imperial College London	Recruiting
London, United Kingdom, SW3 6LY
Contact: Louise E Donnelly, PhD

Sponsors and Collaborators

Imperial College London

Investigators

Principal Investigator:

Louise E Donnelly, PhD

Imperial College London

More Information

Study ID Numbers:	01-024
Study First Received:	September 6, 2005
Last Updated:	September 6, 2006
ClinicalTrials.gov Identifier:	NCT00147082
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:

chemokine
chemokine receptor
neutrophil
lymphocyte
monocyte

Study placed in the following topic categories:

Pulmonary Emphysema
Emphysema
Bronchitis, Chronic
Lung Diseases, Obstructive
Respiratory Tract Infections

Respiratory Tract Diseases
Lung Diseases
Bronchitis
Healthy
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Pathologic Processes
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009